

# Jean M Mulcahy Levy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3842937/publications.pdf>

Version: 2024-02-01

59  
papers

8,677  
citations

361413

20  
h-index

330143

37  
g-index

62  
all docs

62  
docs citations

62  
times ranked

18796  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Targeting autophagy in cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 528-542.	28.4	1,856
3	Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. <i>Cell Research</i> , 2015, 25, 707-725.	12.0	354
4	Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. <i>Cell Death and Differentiation</i> , 2020, 27, 843-857.	11.2	278
5	Targeting autophagy during cancer therapy to improve clinical outcomes. , 2011, 131, 130-141.		208
6	Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors. <i>Cancer Discovery</i> , 2014, 4, 773-780.	9.4	203
7	STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. <i>Cancer Research</i> , 2014, 74, 2579-2590.	0.9	155
8	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. <i>ELife</i> , 2017, 6, .	6.0	128
9	Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. , 2018, 6, 30.		97
10	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
11	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <i>Cancer Immunology Research</i> , 2015, 3, 1165-1174.	3.4	61
12	Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. <i>Pediatric Blood and Cancer</i> , 2013, 60, 700-704.	1.5	56
13	Pediatric Brainstem Gangliogliomas Show <i>BRAF</i> <sup>V600E</sup> Mutation in a High Percentage of Cases. <i>Brain Pathology</i> , 2014, 24, 173-183.	4.1	52
14	Specific expression of PD-L1 in <i>RELA</i> fusion supratentorial ependymoma: Implications for PD-L1 targeted therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26960.	1.5	44
15	Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma. <i>Frontiers in Oncology</i> , 2019, 9, 791.	2.8	39
16	Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28028.	1.5	33
17	NF- $\kappa$ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. <i>Neuro-Oncology</i> , 2017, 19, 1350-1360.	1.2	32
18	Polo-like Kinase $\hat{1}$ as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. <i>BMC Cancer</i> , 2016, 16, 647.	2.6	31

#	ARTICLE	IF	CITATIONS
19	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020, 39, 2305-2327.	5.9	31
20	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	12.8	31
21	Modulation of pediatric brain tumor autophagy and chemosensitivity. <i>Journal of Neuro-Oncology</i> , 2012, 106, 281-290.	2.9	29
22	Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. <i>Cell Death and Disease</i> , 2019, 10, 679.	6.3	24
23	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. <i>Clinical Cancer Research</i> , 2021, 27, 6197-6208.	7.0	20
24	Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. <i>Oncology Reports</i> , 2018, 39, 455-464.	2.6	19
25	Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1984-1994.	4.1	19
26	Using BRAF <sup>V600E</sup> as a marker of autophagy dependence in pediatric brain tumors. <i>Autophagy</i> , 2014, 10, 2077-2078.	9.1	18
27	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. <i>Oncotarget</i> , 2016, 7, 53881-53894.	1.8	17
28	Tumor treating fields in pediatric high-grade glioma. <i>Child's Nervous System</i> , 2017, 33, 1043-1045.	1.1	12
29	SARS-CoV-2 persistence in immunocompromised children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29277.	1.5	11
30	Chordoma Occurs in Young Children With Tuberous Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 418-423.	1.7	10
31	Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 25-39.	3.8	8
32	Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa051.	0.7	8
33	Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1605-1613.	2.4	7
34	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa103.	0.7	6
35	Linking brain tumors and epileptic seizures. <i>Nature Medicine</i> , 2018, 24, 1638-1639.	30.7	3
36	QOL-52. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION. <i>Neuro-Oncology</i> , 2018, 20, i168-i168.	1.2	2

#	ARTICLE	IF	CITATIONS
37	DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii284-iii284.	1.2	2
38	ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1313-1319.	1.7	1
39	LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold. <i>Neuro-Oncology</i> , 2022, 24, i101-i101.	1.2	1
40	OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy. <i>Neuro-Oncology</i> , 2022, 24, i147-i147.	1.2	1
41	EP-04 * ACTIVATION OF THE IL6/STAT3 PATHWAY IN CHILDHOOD EPENDYMOMA IS ASSOCIATED WITH A PRO-INFLAMMATORY TUMOR MICROENVIRONMENT AND A POOR PROGNOSIS. <i>Neuro-Oncology</i> , 2015, 17, iii6-iii6.	1.2	0
42	LGG-37. ASSESSMENT OF EARLY STAGE AUTOPHAGY INHIBITION IN BRAFV600E BRAIN TUMOR CELL RESPONSE TO CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i112-i112.	1.2	0
43	DIPG-66. THE H3K27M MUTATION CAUSES WIDE-RANGING CHANGES MEDIATING DIPG TUMORIGENESIS. <i>Neuro-Oncology</i> , 2018, 20, i62-i62.	1.2	0
44	DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, i64-i65.	1.2	0
45	QOL-58. IMPROVEMENT IN VISUAL ACUITY OF PEDIATRIC PATIENTS WITH BRAIN TUMORS WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, i169-i169.	1.2	0
46	ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i31-i31.	1.2	0
47	TBIO-12. NON-TARGETED MUTATION AND FUSION ANALYSES CAN AID IN CLASSIFICATION AND TREATMENT OF PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i182-i182.	1.2	0
48	EPEN-14. SUBGROUP-SPECIFIC THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
49	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0
50	EPEN-15. RETINOIDS AS POTENTIAL CHEMOTHERAPEUTIC OPTIONS FOR POSTERIOR FOSSA EPENDYMOMA OF CHILDHOOD. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
51	EPEN-09. PRECLINICAL MODELS REVEAL SUBGROUP-STRATIFIED TARGETED THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2019, 21, ii79-ii79.	1.2	0
52	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	1.2	0
53	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	1.2	0
54	Medical and rehabilitation interventions in pediatric central nervous system radiation necrosis: A case report. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28705.	1.5	0

#	ARTICLE	IF	CITATIONS
55	QOL-36. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION. Neuro-Oncology, 2020, 22, iii438-iii438.	1.2	0
56	LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	0
57	MEK inhibition with trametinib is a successful therapy in ganglioglioma. Clinical Case Reports and Reviews, 2020, 6, .	0.1	0
58	491. Persistence of SARS-CoV-2 Infection in Immunocompromised Children. Open Forum Infectious Diseases, 2021, 8, S346-S347.	0.9	0
59	EPID-06. Transfusion related iron overload in pediatric patients with CNS tumors. Neuro-Oncology, 2022, 24, i47-i48.	1.2	0